ESTEVE Acquires Regis Technologies to Expand CDMO Footprint in US

• ESTEVE has acquired US-based Regis Technologies to expand its CDMO operations and establish a physical presence in the United States.

• The acquisition adds around 70 staff and increases ESTEVE’s small-molecule API development and manufacturing capacity.

ESTEVE, a global contract development and manufacturing organisation (CDMO) operating under the Esteve Química brand, has acquired Regis Technologies, a US-based API CDMO headquartered in Chicago.

The acquisition marks ESTEVE’s entry into the United States market with a physical presence, broadening its CDMO solutions for innovative small-molecule active pharmaceutical ingredients (APIs) from pre-clinical development through to commercial manufacturing. Regis Technologies has been active in the US for over 65 years, offering services such as process R&D, analytical and stability studies, cGMP API manufacturing, and CMC support.

“This acquisition is adding capabilities, as well as development and manufacturing capacity, while increasing the team of ESTEVE’s CDMO business with around 70 skilled people,” said Joan Petit, Chief Industrial Operations Officer of ESTEVE and General Manager of Esteve CDMO.

According to the press release, the move aligns with ESTEVE’s strategy to strengthen its position in key global markets and deliver integrated contract manufacturing services. ESTEVE CDMO operates facilities in Spain, Mexico, and China, and now adds the United States to its manufacturing network.

Scott Aladeen, President and CEO of Regis Technologies, noted that joining ESTEVE means becoming part of a company with shared values and a long-term customer focus.